Conference Description:

A thorough 2-day event addressing emerging strategies for drug development within Neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative and neuropsychiatric diseases.

This in-depth event will detail the journey of neuroscience discovery from initial lead through to clinical trials, bringing together leading companies for discussion, knowledge-sharing and focused networking.

The 2023 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Below are some of the key speakers for Neuroscience Drug Development Europe 2023.

Sebastien Gillotin - Associate Principal Scientist at MSD

Pekka Kallunki - Principal Scientist at Lundbeck

Iain Chessell, Global Head of Neuroscience at AstraZeneca

Ludovic Collin, Section Leader Neuroimmunology at Roche

Magnus Walter, Senior Director Drug Discovery, Medicinal Chemistry and Screening Biology at AbbVie

Jenny Barnett, Chief Executive Officer at Monument Therapeutics